Entrada Therapeutics (TRDA) said Monday it has received approval from the UK's Medicines and Healthcare Products Regulatory Agency and Research Ethics Committee to launch a phase 1/2 multiple ascending dose trial of its experimental ENTR-601-45 treatment of Duchenne muscular dystrophy.
The clinical study covers patients with a confirmed mutation in the Duchenne muscular dystrophy gene amenable to exon 45 skipping.
Entrada said it is on course to begin the trial in Q3.
Duchenne muscular dystrophy causes skeletal and heart muscle weakness that quickly gets worse with time.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.